S-Mephenytoin hydroxylation phenotypes in a Jordanian population

Hakam F. Hadidi, Yacoub M. Irshaid, Raymond L. Woosley, Jeffrey R. Idle, David A. Flockhart

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We tested the ability of 194 unrelated, healthy Jordanian volunteers to metabolize S-mephenytoin. Mephenytoin (100 mg) was coadministered with debrisoquin (10 mg) orally and urine was collected for 8 hours. Mephenytoin metabolism was tested according to three measures: the amount of 4-hydroxymephenytoin, the S R enantiomeric ratio, and the presence of a polar, acid-labile metabolite in urine collected for 8 hours after the dose. The S R ratio and the presence of the acid-labile metabolite were determined in the urine of 16 patients who had low amounts of 4-hydroxymephenytoin (log hydroxylation index ≥1). On examination of these three parameters of oxidation status, nine subjects were found to be poor metabolizers of mephenytoin by all three parameters. Thus 4.6% (95% confidence interval of 1.6% to 7.6%) of Jordanian subjects studied were poor metabolizers of mephenytoin. According to the Hardy-Weinberg Law, the frequency of the recessive autosomal gene controlling the poor metabolizer status of mephenytoin was predicted to be 0.215% (95% confidence interval of 0.146% to 0.283%). These results are on the same order of magnitude as those determined in European white populations and constitute the first report in Arab populations.

Original languageEnglish (US)
Pages (from-to)542-547
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume58
Issue number5
StatePublished - Nov 1995
Externally publishedYes

Fingerprint

Mephenytoin
Hydroxylation
Phenotype
Population
Urine
Debrisoquin
Confidence Intervals
Recessive Genes
Acids
Healthy Volunteers

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hadidi, H. F., Irshaid, Y. M., Woosley, R. L., Idle, J. R., & Flockhart, D. A. (1995). S-Mephenytoin hydroxylation phenotypes in a Jordanian population. Clinical Pharmacology and Therapeutics, 58(5), 542-547.

S-Mephenytoin hydroxylation phenotypes in a Jordanian population. / Hadidi, Hakam F.; Irshaid, Yacoub M.; Woosley, Raymond L.; Idle, Jeffrey R.; Flockhart, David A.

In: Clinical Pharmacology and Therapeutics, Vol. 58, No. 5, 11.1995, p. 542-547.

Research output: Contribution to journalArticle

Hadidi, HF, Irshaid, YM, Woosley, RL, Idle, JR & Flockhart, DA 1995, 'S-Mephenytoin hydroxylation phenotypes in a Jordanian population', Clinical Pharmacology and Therapeutics, vol. 58, no. 5, pp. 542-547.
Hadidi HF, Irshaid YM, Woosley RL, Idle JR, Flockhart DA. S-Mephenytoin hydroxylation phenotypes in a Jordanian population. Clinical Pharmacology and Therapeutics. 1995 Nov;58(5):542-547.
Hadidi, Hakam F. ; Irshaid, Yacoub M. ; Woosley, Raymond L. ; Idle, Jeffrey R. ; Flockhart, David A. / S-Mephenytoin hydroxylation phenotypes in a Jordanian population. In: Clinical Pharmacology and Therapeutics. 1995 ; Vol. 58, No. 5. pp. 542-547.
@article{51855226b25b4b9ba03b84ad39b28a7f,
title = "S-Mephenytoin hydroxylation phenotypes in a Jordanian population",
abstract = "We tested the ability of 194 unrelated, healthy Jordanian volunteers to metabolize S-mephenytoin. Mephenytoin (100 mg) was coadministered with debrisoquin (10 mg) orally and urine was collected for 8 hours. Mephenytoin metabolism was tested according to three measures: the amount of 4-hydroxymephenytoin, the S R enantiomeric ratio, and the presence of a polar, acid-labile metabolite in urine collected for 8 hours after the dose. The S R ratio and the presence of the acid-labile metabolite were determined in the urine of 16 patients who had low amounts of 4-hydroxymephenytoin (log hydroxylation index ≥1). On examination of these three parameters of oxidation status, nine subjects were found to be poor metabolizers of mephenytoin by all three parameters. Thus 4.6{\%} (95{\%} confidence interval of 1.6{\%} to 7.6{\%}) of Jordanian subjects studied were poor metabolizers of mephenytoin. According to the Hardy-Weinberg Law, the frequency of the recessive autosomal gene controlling the poor metabolizer status of mephenytoin was predicted to be 0.215{\%} (95{\%} confidence interval of 0.146{\%} to 0.283{\%}). These results are on the same order of magnitude as those determined in European white populations and constitute the first report in Arab populations.",
author = "Hadidi, {Hakam F.} and Irshaid, {Yacoub M.} and Woosley, {Raymond L.} and Idle, {Jeffrey R.} and Flockhart, {David A.}",
year = "1995",
month = "11",
language = "English (US)",
volume = "58",
pages = "542--547",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - S-Mephenytoin hydroxylation phenotypes in a Jordanian population

AU - Hadidi, Hakam F.

AU - Irshaid, Yacoub M.

AU - Woosley, Raymond L.

AU - Idle, Jeffrey R.

AU - Flockhart, David A.

PY - 1995/11

Y1 - 1995/11

N2 - We tested the ability of 194 unrelated, healthy Jordanian volunteers to metabolize S-mephenytoin. Mephenytoin (100 mg) was coadministered with debrisoquin (10 mg) orally and urine was collected for 8 hours. Mephenytoin metabolism was tested according to three measures: the amount of 4-hydroxymephenytoin, the S R enantiomeric ratio, and the presence of a polar, acid-labile metabolite in urine collected for 8 hours after the dose. The S R ratio and the presence of the acid-labile metabolite were determined in the urine of 16 patients who had low amounts of 4-hydroxymephenytoin (log hydroxylation index ≥1). On examination of these three parameters of oxidation status, nine subjects were found to be poor metabolizers of mephenytoin by all three parameters. Thus 4.6% (95% confidence interval of 1.6% to 7.6%) of Jordanian subjects studied were poor metabolizers of mephenytoin. According to the Hardy-Weinberg Law, the frequency of the recessive autosomal gene controlling the poor metabolizer status of mephenytoin was predicted to be 0.215% (95% confidence interval of 0.146% to 0.283%). These results are on the same order of magnitude as those determined in European white populations and constitute the first report in Arab populations.

AB - We tested the ability of 194 unrelated, healthy Jordanian volunteers to metabolize S-mephenytoin. Mephenytoin (100 mg) was coadministered with debrisoquin (10 mg) orally and urine was collected for 8 hours. Mephenytoin metabolism was tested according to three measures: the amount of 4-hydroxymephenytoin, the S R enantiomeric ratio, and the presence of a polar, acid-labile metabolite in urine collected for 8 hours after the dose. The S R ratio and the presence of the acid-labile metabolite were determined in the urine of 16 patients who had low amounts of 4-hydroxymephenytoin (log hydroxylation index ≥1). On examination of these three parameters of oxidation status, nine subjects were found to be poor metabolizers of mephenytoin by all three parameters. Thus 4.6% (95% confidence interval of 1.6% to 7.6%) of Jordanian subjects studied were poor metabolizers of mephenytoin. According to the Hardy-Weinberg Law, the frequency of the recessive autosomal gene controlling the poor metabolizer status of mephenytoin was predicted to be 0.215% (95% confidence interval of 0.146% to 0.283%). These results are on the same order of magnitude as those determined in European white populations and constitute the first report in Arab populations.

UR - http://www.scopus.com/inward/record.url?scp=0028892079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028892079&partnerID=8YFLogxK

M3 - Article

C2 - 7586948

AN - SCOPUS:0028892079

VL - 58

SP - 542

EP - 547

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -